Official Journal of the Human Genome Organisation
Polymorphism | NW control | NW patients | OW control | OW patients | |
---|---|---|---|---|---|
(CA) n | Allele | 2n = 712 | 2n = 568 | 2n = 894 | 2n = 1,448 |
(CA)11 | 43 (6.1) | 50 (8.8) | 52 (5.8) | 97 (6.7) | |
(CA)12 | 6 (0.8) | 7 (1.2) | 8 (0.9) | 16 (1.1) | |
(CA)13 | 126 (17.7) | 111 (19.5) | 174 (19.5) | 270 (18.6) | |
(CA)14 | 14 (2.0) | 9 (1.6) | 25 (2.8) | 31 (2.1) | |
(CA)15 | 398 (55.9) | 309 (54.4) | 479 (53.6) | 789 (54.5) | |
(CA)16 | 122 (17.1) | 76 (13.4) | 145 (16.2) | 228 (15.8) | |
(CA)17 | 3 (0.4) | 6 (1.1) | 11 (1.2) | 17 (1.2) | |
OR (95% CI)* | 0.94 (0.75–1.17) | 1.04 (0.88–1.23) | |||
P value | 0.63 | 0.70 | |||
rs1061622 | MAF, G | 26.5 | 28.8 | 26.4 | 26.0 |
Genotype | n = 356 | n = 283 | n = 447 | n = 713 | |
GG | 21 (5.9) | 26 (9.2) | 25 (5.6) | 48 (6.7) | |
GT | 147 (41.3) | 111 (39.2) | 168 (37.6) | 288 (40.4) | |
TT | 188 (52.8) | 146 (51.6) | 254 (56.8) | 377 (52.9) | |
OR (95% CI)** | 1.05 (0.77–1.43) | 1.17 (0.92–1.49) | |||
P value | 0.82 | 0.21 | |||
rs3397 | MAF, T | 39.9 | 42.9 | 44.4 | 40.4 |
Genotype | n = 356 | n = 282 | n = 447 | n = 718 | |
TT | 50 (14.0) | 51 (18.1) | 87 (19.5) | 106 (14.8) | |
CT | 184 (51.7) | 140 (49.6) | 223 (49.9) | 368 (51.2) | |
CC | 122 (34.3) | 91 (32.3) | 137 (30.6) | 244 (34.0) | |
OR (95% CI)** | 1.09 (0.78–1.52) | 0.85 (0.66–1.10) | |||
P value | 0.65 | 0.25 |